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Abstract
Background: Vasectomy is currently the only long-acting contraceptive option available for men, despite
increasing demand and potentially significant positive impacts on human health of additional male contraceptive
options. Vasalgel ™ is a high molecular weight hydrogel polymer being developed as a non-hormonal long-acting
reversible male contraceptive. Vasalgel consists of styrene-alt-maleic acid dissolved in dimethyl sulfoxide, which is
distinct from styrene-alt-maleic anhydride materials previously studied.
Methods: The goal of the study was to determine the contraceptive efficacy of two test articles with different
levels of styrene maleic acid (100 %, and 80 % acid/20 % anhydride). The test articles were injected bilaterally in the
vasa deferentia of mature male rabbits. Post-implantation analyses of semen parameters were completed over a
12 month period and compared to baseline measures of sperm concentration, motility and forward progression.
Results: Both test articles were effective in blocking the passage of spermatozoa through the vasa deferentia in the
12 subjects completing the study. A significant decrease in sperm concentration occurred following implantation of
the test material, with no measurable sperm concentration except for a few samples in one animal that were
markedly oligospermic. Vasalgel produced a rapid onset of azoospermia, with no sperm in semen samples collected
as early as 29–36 days post-implantation, and was durable over a 12 month period.
Conclusion: This study indicated that Vasalgel is an effective non-hormonal long-acting male contraceptive in a
rabbit model.
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Background
The availability and use of contraceptives has far-reaching
implications for human health and wellbeing. An estimated
85 million unintended pregnancies occur annually world-
wide, with half ending in abortion and 13 % in miscarriage
[1]. The unmet need for modern contraception in develop-
ing countries was estimated at 222 million in 2012. Serving
this need would prevent 54 million unintended pregnan-
cies, including 26 million abortions [2]. Even when avail-
able, male and female contraceptive methods are often
used inconsistently or discontinued early for a myriad of
reasons (e.g., lack of access to product supply or prescrip-
tions; unwanted side effects or health concerns; seeking a
more effective method), accounting for 33 million of the
accidental pregnancies worldwide [3, 4].
While several options for long-acting contraception
are available to women, vasectomy is the sole long-
acting method available to men. Vasectomy is safe and
very effective but is generally considered permanent
because its reversal is technically difficult, expensive,
and may not be successful in restoring fertility (e.g., [5]).
Reversible male methods of contraception (male condom,
spermicide, periodic abstinence and withdrawal) have rela-
tively high failure rates and are not well accepted by vari-
ous populations [6]. A large number of potential male
contraceptives have been studied, including hormonal
methods with ongoing clinical trials [7]. However,
given the risks and known side effects for female hor-
monal birth control, ranging from venous thrombo-
embolism to excessive menstrual bleeding, risks may
be anticipated in a hormonal approach for men as
well, and focusing effort on non-hormonal alternatives
is important [8]. Demand for a non-hormonal, highly
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effective contraceptive for men is increasing, with
uptake expected to reduce the incidence of unplanned
pregnancy and its related sequelae [9].
A likely target for non-hormonal male contraception is
the vas deferens, which carries sperm from the epididy-
mis to the ejaculatory duct. A number of products have
been tested that do not allow viable sperm to pass
through the vasa deferentia [10]. Examples include solid
intra-vas occlusion devices (made of polyurethane or
silicone), vas clips, and copper mesh filtering devices
[11–15]. Most vas-occlusive products have suffered from
limited reversibility, side effects or problems with long
term efficacy.
Intra-vas injections of polymers that become hydrogels
are very promising as a device for male contraception.
One product, called RISUG® (Reversible Inhibition of
Sperm Under Guidance) based on styrene maleic anhyd-
ride (SMA anhydride), has been studied in India for over
three decades [16]. The researchers report long-term
efficacy in preclinical and human studies [17, 18], with
Phase III clinical trials underway since 2002. Fertility
was returned in rats following removal of the material
by flushing with bicarbonate [19, 20] and in monkeys
through palpation and percutaneous electrical and vibratory
stimulation [21–23]. RISUG reportedly works by blocking
sperm transport, creating an incompatible pH level, and
generating a positive charge that ruptures the acrosomal
membrane of the negatively charged sperm head [10].
Vasalgel™ is a high molecular weight polymer being
developed in the US as a contraceptive device for men.
While both entail an injection into the vas deferens, Vasal-
gel has important differences in composition and function
when compared to RISUG. Vasalgel is comprised mainly of
styrene-alt-maleic acid (SMA acid). Because SMA anhy-
drides may hydrolyze in aqueous conditions, SMA acid
without SMA anhydride has the potential advantages of a
less complex process of production and long term stability
without concern for hydrolysis, creating a more feasible
regulatory path. After implantation, the SMA acid forms a
hydrogel that appears to be tissue adherent, fills the lumen
of the vas deferens and acts as a mechanical barrier to the
passage of sperm. The purpose of the present study was to
determine the efficacy of the Vasalgel SMA polymer hy-
drogel to produce rapid and durable contraception over
12 months in a rabbit model. Because efficacy of primarily
SMA anhydride preparations (e.g. RISUG) is known and
efficacy of SMA acid preparations was neither known nor
assured, preparations of SMA acid and mixed SMA acid
and anhydride were compared.
Methods
Test articles
Vasalgel test articles consisted of 25 % solutions by weight
of SMA in DMSO. The average molecular weight (Mw) of
the SMA anhydride (Poly(Styrene-co-Maleic Anhydride,
CAS Registry Number: 9011-13-6) was 330 kDa according
to standardized gel permeation chromatography (GPC)
methodology (Jordi Labs, Mansfield, MA, USA). The
SMA acid (Poly(styrene-alt-maleic acid, CAS Registry
Number: 25736-61-2) was made by hydrolysis of the
anhydride and had a Mw of 360 kDa. Test article #1
contained only SMA acid (referred to as “100 % acid”).
Test article #2 was prepared by weighing appropriate
amounts of the SMA acid and SMA Anhydride and to
achieve a mixture of 80 % SMA acid and 20 % SMA
anhydride by weight (referred to as “80:20 mix”) in
DMSO. The final test articles were prepared and packaged
in a nitrogen atmosphere in 2 ml glass vials by Poly-
sciences, Inc. (Warrington, PA, USA). The 80:20 mix was
selected to provide a comparison with the 100 % SMA
Acid. This was based upon an evaluation of the material
responses in the presence in saline. An increase in the
amount of anhydride in the mix resulted in a less flexible
and harder material which was not desired within the vas.
Subjects, housing and care
The studies were performed using 15 mature male and
three mature female New Zealand White rabbits that
averaged 26.2 weeks of age (SD = 0.37 weeks) and
weighed an average of 3.7 kg (SD = 0.10 kg) on arrival
from Harlan Laboratories, Oxford, MI. The animals
were screened for health conditions and acclimated for
7 days. Housing and care protocols used recommendations
of the National Centre for the Replacement, Refinement,
and Reduction of Animals in Research [24]. Rabbits were
individually housed in stainless steel cages in temperature-
and light- controlled rooms meeting the requirements
specified in the FELASA publication entitled Euroguide
[25] and fed Purina® Rabbit Chow™ (Purina Mills, St. Louis,
MO, USA). The rabbits also had regular access to a play
area within the same room, where they could socialize and
exercise. All animals were checked at least twice daily for
viability and general health during the entire period of the
study. The female rabbits were only used as teaser animals
when collecting semen specimens. They were housed in
the same room as the male rabbits and were placed
for adoption at the end of the study. All animal proce-
dures were approved by the Loyola University Chicago
Institutional Animal Care and Use Committee.
Experimental design
Baseline semen sample collection was attempted for all 15
male rabbits for an average of 6 weeks (SD = 2.7 weeks)
prior to implantation of the Vasalgel device. All rabbits
then received bilateral vas deferens implants of 100 % acid
(n = 8) or 80:20 mix (n = 7). Semen collection began again
at an average of 10.8 weeks (SD = 4.9 weeks) post implant-
ation. Semen collection continued approximately weekly
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until azoospermia was observed. Semen was then
collected twice monthly until approximately 12 months
post injection.
Implantation of test articles
Animals were weighed, given an antibiotic (Baytril®
[Bayer Healthcare, KS, USA] 5 mg/kg) and then anesthe-
tized with an intramuscular injection of xylazine HCl
(4 mg/kg) and ketamine HCl (50 mg/kg) and a subcuta-
neous injection of acepromazine maleate (1.0 mg/kg). A
1 cm suprapubic transverse incision was made in the
midline approximately 2 cm cephalad to the pubic sym-
physis. The spermatic cords were brought up through the
incision and isolated. The cremasteric fascia was incised
in a longitudinal fashion and the vas deferens isolated with
its blood supply.
The isolated right and left vasa deferentia were elevated
and injected with approximately 100–120 μl of test article
in about 30–40 seconds using a 24 gauge 1.6 cm catheter
(Quik-Cath by Baxter, Deerfield, IL). This volume of
material was expected to fill the vas deferens to an
approximate length of 2 cm based on preliminary studies
in euthanized rabbits. The catheter was then removed, the
vasa deferentia gently compressed for about 30 s and the
vasal muscularis at the site of injection identified with
a 6-0 Prolene suture. The vas deferens was returned
to the spermatic cord and the site closed with 4-0
nylon sutures. The rabbits were given antibiotic Baytril®
(5 mg/kg) (Bayer Healthcare, KS, USA) once per day for
7 days post-operatively and pain medication buprenor-
phine HCl (0.2 ml) every eight hours for 72 h post-
operatively. All surgical procedures were performed by the
same surgical team.
Semen collection and evaluation
Semen collections were performed using a warmed artifi-
cial vagina semen-collection device designed for use with
the rabbit and a “teaser” female to encourage mounting
(e.g., [26]). Semen specimens were evaluated for volume,
total sperm count, sperm motility and forward progres-
sion using standard manual methods. Additionally, any
observations of possible sperm were recorded when there
were too few sperm to count using standard methods.
Euthanasia and necropsy
Rabbits that died during the 23 month study received a
necropsy following standard protocol with particular
attention to the reproductive tract.
The vas deferens from six animals were harvested and
immersed in 10 % neutral buffered formalin for fixation.
The vasa were from one animal that died three days
after implant, three animals necropsied during the
course of the study due to not providing semen samples
or behavioral issues (Days 189, 214 and 248) and two
after extended exposure to Vasalgel (Days 572 and 538).
The tissues were processed, sectioned and stained with
hematoxylin and eosin utilizing standard methods for
evaluation.
Data analysis
Data were summarized by subject. The efficacy of the
test article to block sperm was evaluated by compar-
ing the mean sperm parameters (sperm concentration,
forward progression and motility) for each subject by
condition (baseline vs. post-implant) and by test art-
icle (100 % acid, 80:20 mix). Repeated measures
analysis of variance using a 2 × 2 design was used to
statistically test the condition x test article signi-
ficance using the program Statistica (StatSoft, Inc.
Tulsa, OK, USA). T-test for independent samples was
conducted to determine any difference in sperm parame-
ters at baseline. A significance level of p < 0.05 was
determined. Data are presented as mean ± standard
deviation.
Results
Injection of the test material was successfully accom-
plished in all male subjects. The time to complete
the implantation surgery decreased 33 % from the
first five to the last five procedures (54.0 ± 21.6 vs.
36.0 ± 10.8 min) as the surgeon gained experience
identifying and injecting the small and fragile rabbit
vasa deferentia. Extravasation of a small amount of test
material occurred in four vasa deferentia and one became
distended when the material was injected.
Twelve animals (n = 6 in each of the 100 % acid and
80:20 mix groups) from the original 15 were retained in
the study. Three rabbits died postoperatively without
precipitating illness, apparently from surgical trauma as
the operative technique was being refined. In two of the
subjects (one 100 % acid, one 80:20 mix), the reproduct-
ive tract became engorged with blood caudal to the
injection site, involving a single vas deferens in one male
and both testes, vasa deferentia and epididymides in the
other male. There were no direct observations of inflam-
mation due to the presence of Vasalgel within the vasa.
All other organs appeared normal. The third male
(100 % acid) was found dead three days after surgery
with no obvious cause. All organs, including the repro-
ductive tract, appeared normal and the incision site was
healing normally. There were no direct observations of
any inflammation or tissue damage due to the presence
of Vasalgel. One of the twelve study subjects died six
months following the implant surgery due to neck
trauma unrelated to surgery or the presence of Vasalgel.
The reproductive tract appeared normal and his data
were included in analyses. See Table 1 for information
on each subject.
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A total of 264 semen samples were successfully
collected (of 459 attempts) from the 12 subjects over the
course of the study (Table 1). Most unsuccessful
attempts were due to ejaculation outside the artificial
vagina. An average of 2.6 ± 0.5 samples were collected
per subject in the baseline condition and 19.4 ± 7.6 were
collected per subject over the 12 months following
implantation. Semen volume was 0.30 ± 0.07 ml dur-
ing baseline and 0.76 ± 0.30 ml after implantation of
the test article.
Significant decreases in sperm measurements occurred
in all 12 animals following implant of the test article
(Table 1). Sperm concentration during baseline was
233.1 ± 81.2 × 106 sperm/ml (range of individual aver-
ages 130.7 – 324.0 × 106 sperm/ml). Semen samples
following implantation contained no measurable sperm
using standard methods during the 12 month follow-up
period, except for one rabbit with very low sperm
concentrations measured in five of the first 13 semen
samples but eventually provided semen samples with no
spermatozoa present in the ejaculate. The average post-
implantation sperm concentration from this animal was
0.24 × 106 sperm/ml.
At baseline, the mean percentage of motile sperm was
78.2 ± 6.8 and the mean percentage showing forward
progression was 42.5 ± 7.2. Following implant, these pa-
rameters were zero in all samples.
Semen analysis also included qualitative observations
of small numbers of sperm or fragments in the samples,
which were too few to reliably count using standard
methods. Of 233 samples collected after implantation
with the contraceptive, three rabbits in the 80:20 mix
group had very few sperm in their first semen sample
(occurring at day 29, 35 and 64 post-implant) indicating
that virtually all sperm were blocked.
There was no significant difference in the three
baseline semen parameters for the two test articles (all
p > 0.2). Statistical analysis of the impact of condition
(baseline vs. implant) by test article (100 % vs 80:20 mix)
indicated a significant condition effect with sperm
concentration being significantly lower during the im-
plant condition (F = 90.0, p < 0.001) (Fig. 1). The test
article was not influential in this relationship since the
test article and condition x test article interactions
were not significant (p > 0.05). It was not possible to
conduct a similar statistical test on the motility and
forward progression because there was no variability in
the implant condition (due to zero motility and pro-
gression values).
Histological evaluation of the vasa deferentia of six
subjects was completed. The vas deferens in the one
animal after three days of implant exposure exhibited an
intraluminal accumulation of non-fibrillar eosinophilic
to amphophilic homogenous material (Fig. 2a). The
material accumulated in the lumen was devoid of in-
flammatory cells and epithelial cells. One animal exhib-
ited a moderate accumulation of spermatozoa embedded
in the material and the remaining animals evaluated
exhibited scattered spermatozoa or no spermatozoa
embedded in the intraluminal material. The mucosal
epithelium in all animals demonstrated some degree of
attenuation, taking on a cuboidal to flattened appearance
in contrast to the ciliated columnar epithelium observed
in regions devoid of intraluminal material. Segmental
mucosal epithelial loss without inflammation was ob-
served. In some treated animals, the mucosal epithelium
Table 1 Number of semen samples and sperm concentration during baseline and after implantation of the test articles for each subject
Baseline Implantation
Animal ID Test article # Semen samples Sperm Concentration × 106
sperm/ml (mean ± SD)
# Semen samples Sperm Concentration × 106
sperm/ml (mean ± SD)
Outcome
8949 100 % acid 3 228.3 ± 78.5 0.00
8960 100 % acid 3 211.7 ± 175.3 4 0.00 Died six months
after implantation
8963 100 % acid 3 194.3 ± 146.3 13 0.00
8964 100 % acid 2 414.0 ± 179.6 24 0.00
8968 100 % acid 2 165.5 ± 170.4 22 0.00
8972 100 % acid 3 189.0 ± 52.5 24 0.00
8956 80:20 mix 3 130.7 ± 76.3 18 0.00
8958 80:20 mix 3 148.0 ± 59.3 27 0.00
8965 80:20 mix 2 296.5 ± 146.4 28 0.24 ± 1.0
8966 80:20 mix 2 324.0 ± 107.5 23 0.00
8970 80:20 mix 3 267.3 ± 170.0 8 0.00
8971 80:20 mix 2 228.0 ± 63.6 25 0.00
# = number
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was replaced by round to polygonal cells with abun-
dant eosinophilic cytoplasm and round to oval nuclei
(Fig. 2b,c). These cells often exhibited close associ-
ation to each other and were interpreted as epit-
helioid macrophages. Larger cells were also present
with similar cytoplasm but contained multiple round
to oval nuclei (ranging from 2–10 nuclei within a
cell), interpreted as multinucleated giant cells. This
replacement of mucosal epithelium was observed in
both a segmental and a circumferential manner in
the treated animals.
Similar material present in the lumen of the vas deferens
was also observed in the some surrounding interstitial
connective tissue interpreted as extraluminal hydrogel
(Fig. 2d). The accumulation of this material was often
arranged in a multifocal to coalescing nodular pattern and
was associated with a surrounding rim of epithelioid
macrophages and multinucleated giant cells. The mul-
tinucleated giant cells observed in the interstitial space
frequently exhibited higher nuclei numbers than those
seen at the mucosal surface of the vas deferens. Both test
articles (100 % SMA and 80:20 mix) were similar in the
Fig. 1 Sperm concentration during baseline and implant conditions for the two test articles. Difference between conditions was significant (p < 0.001)
Fig. 2 Rabbit ductus deferens containing SMA hydrogel. a Longitudinal section (100X magnification) of vas deferens containing hydrogel
appearing as eosinophilic homogenous luminal material. Arrowheads depict the mucosal epithelium. Muscularis (M), vas deferens lumen (L).
b Longitudinal section (400X magnification) of vas deferens containing hydrogel. Arrowheads depict the attenuated mucosal epithelium in this
section. Scattered spermatozoa are present (arrows). Muscularis (M), vas deferens lumen (L). c Cross section (200X magnification) of vas deferens.
A layer of epithelioid macrophages replaces the luminal epithelium in this section (★). Muscularis (M), vas deferens lumen (L). d Interstitial
hydrogel with associated granulomatous inflammation (400X magnification). Arrows depict epithelioid macrophages and multinucleated giant
cells surrounding eosinophilic to amphophilic material in the interstitium
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degree of epithelial attenuation present as well as the in-
flammation present at the mucosa and in the interstitium.
The histological observations did not appear to be
dependent upon the duration of Vasalgel exposure.
Discussion
Despite the need for male contraception and the fact
that vas-occlusive devices have been tested for de-
cades, no product has been successfully introduced to
the market. The characteristics of the occlusive mater-
ial are critical and previous attempts to use solid or
semi-solid material had side effects or unacceptable
efficacy. For example, a urethane intra-vas device
tested in 288 men in China proved to be only 94.3 %
effective, not matching vasectomy’s 98.6 % effective-
ness in the study [12].
The characteristics of the Vasalgel test articles likely
influenced the ability of the hydrogels to provide effect-
ive contraception [16]. Previous investigators of styrene-
based vas deferens contraceptives have reported efficacy
with anhydride-based formulations [16]. However, anhy-
drides are susceptible to hydrolysis to an acid over time
in the presence of water. A 100 % SMA acid-based
formulation, rather than a styrene maleic anhydride
formulation should result in greater stability under long
term storage conditions. This study addresses the ques-
tion of whether a 100 % acid SMA formulation will
provide the same efficacy as an anhydride or acid-
anhydride mix formulation. The current study demon-
strate that both 100 % acid and 80:20 mix formulas
dissolved in DMSO were effective in blocking the vas
deferens to the passage of spermatozoa. A significant
decrease in sperm concentration occurred following
implantation of the test material, with 99.6 % of semen
samples collected having no measurable sperm concen-
tration. Although a non-significant finding, the efficacy
of the 100 % acid test article was supported by the
finding that the only rabbits that had small numbers of
sperm in the initial semen samples were from the 80:20
mix group.
The onset of azoospermia was rapid and durable over
the 12 month period. Rabbits that had samples collected
as early as 29–36 days post implantation were azoosper-
mic. As described above, qualitative observations indi-
cated that only three subjects evidenced a few sperm
visible in their first sample. Histologically, vas deferens
from both the 100 % SMA group and the 80:20 mix group
exhibited mucosal flattening with epithelial attenuation.
Granulomatous inflammation was seen in some animals
in both groups and manifested as either mucosal replace-
ment by the inflammatory cell population or interstitial
nodular inflammation with intralesional polymer. The
presence of some extraluminal gel may have occurred
by extravasation of the material immediately following
injection. However, the tissue response appears to be
minimal with characteristics of a normal foreign body
response. These changed appear to be similar in the
vasa from both the short term and the longer term
exposures to Vasalgel.
The SMA acid polymer dissolved in DMSO appears to
provide functional advantages as a contraceptive. Advan-
tages may stem from the ability of DMSO to rapidly
transit through an aqueous milieu as well as cells and
tissues [27], resulting in diffusion of DMSO from the
vasa deferentia and formation of a flexible, tissue ad-
herent hydrogel. The maleic acid groups in SMA are
thought to be essential to hydrogel formation and
hydrolysis of the maleic anhydride groups in the 80:20
mix implants to the maleic acid form of the SMA may
also facilitate hydrogel formation [28]. Hydrogels allow
transit of many water soluble molecules but not larger
structures such as spermatozoa, and this hydroperme-
ability may reduce hydrostatic pressure in the epididymis
and rete testis. The implant remains in a soft gel-like
state, with the ability to flex and adhere to the vasa
deferentia and minimize any accommodation of the vas
to the presence of the test article. This is in contrast to
solid vas plug devices, which may have failed due to an
increase of the vas diameter from the presence of a
solid material within the lumen of the vasa. A dilation
of the vas has been observed in past studies when a
solid plug was inserted into a vas for an extended
period of time which can then allow passage of the
spermatozoa around the solid plug [Waller D (2012)
Unpublished observations].
Three rabbits died following the surgery from apparent
surgical trauma. One was implanted with 80:20 mix and
two were implanted with the 100 % acid formulations.
None of the deaths appeared to be related to the pres-
ence of the injected material. The anatomy of the rabbit
dictates abdominal surgery to access and inject the vasa
deferentia, which entails higher surgical risk and trauma
than accessing the human vas. In humans, the Vasalgel
contraceptive implantation can be conducted using the
minimally invasive No Scalpel Vasectomy procedure to
access and inject Vasalgel [29].
It has been suggested that the method of contraceptive
action of the primarily anhydride SMA material (RISUG)
was through deactivating sperm passing by the gel,
which lined the walls of the vas lumen without complete
occlusion. This was reportedly achieved because the
hydrogel lowered pH and induced electrical charge dis-
turbances that impaired acrosome function [16, 30, 31].
In this study, we found no evidence that measurable
numbers of sperm passed through the primarily SMA
acid material. The Vasalgel product appears to be effective
by blocking sperm from passing through the vas deferens
as its primary mode of action.
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Conclusions
Both 100 % SMA acid and the 80:20 mix test articles
injected into the rabbit vasa deferentia produced rapid
onset of azoospermia that was durable throughout a
12 month period, proving effectiveness in the rabbit
model. The effects on the structure of the vas appear to
be minor and support the potential for a return to full
function following removal. Further study of this new
contraceptive, including success in flushing the gel from
the vasa deferentia to return sperm flow, is needed to
confirm its potential as a long-acting reversible male
contraceptive.
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